MedTrace Logo

CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

NCT04987268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1029

Last updated 2025-09-10

No results posted yet for this study

Summary

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

Conditions

  • ACS
  • Clonal Hematopoiesis of Indeterminate Potential
  • Smoking Cessation

Interventions

GENETIC

clonal hematopoiesis of indeterminate potential

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Sponsors & Collaborators

  • Shenyang Northern Hospital

    lead OTHER

Principal Investigators

  • Yaling Han, MD · The General Hospital of Northern Theater Command

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-20
Primary Completion
2022-08-20
Completion
2023-08-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04987268 on ClinicalTrials.gov